| アブストラクト | OBJECTIVES: To describe inpatient and outpatient cardiac rehabilitation (CR) utilization patterns over time and by subgroups among patients admitted for acute heart failure (AHF) in Japan. BACKGROUND: Cardiac rehabilitation (CR) is a crucial secondary prevention strategy for patients with heart failure. While the number of older patients with AHF continues to rise, trends in inpatient and outpatient CR participation following AHF in Japan have not been described to date. METHODS: We conducted a retrospective cohort study of adult patients hospitalized for AHF in Japan between April 2008 and December 2020. Using data from the Medical Data Vision database, we measured trends in inpatient and outpatient CR participation following AHF. Descriptive analyses and summary statistics for AHF patients by CR participation status were reported. RESULTS: The analytic cohort included 88,052 patients. Among these patients, 37,810 (42.9%) participated in inpatient and/or outpatient CR. Of those, 36,431 (96.4%) participated in inpatient CR only and 1,277 (3.4%) participated in both inpatient and outpatient CR. Rates of inpatient CR rose more than 6-fold over the study period, from 9% in 2009 to 55% in 2020, whereas rates of outpatient CR were consistently low. CONCLUSIONS: The rate of inpatient CR participation among AHF patients in Japan rose dramatically over a 12-year period, whereas outpatient CR following AHF was vastly underutilized. Further study is needed to assess the clinical effectiveness of inpatient CR and to create infrastructure and incentives to support and encourage outpatient CR. |
|---|
| 組織名 | Institute for Health, Health Care Policy and Aging Research, Center for;Pharmacoepidemiology and Treatment Science, Rutgers University, New Brunswick,;New Jersey, United States of America.;Department of Preventive Medicine, Yonsei University College of Medicine, Seoul,;Republic of Korea.;Institute for Innovation in Digital Healthcare, Yonsei University, Seoul,;Center for Observational Research and Data Science, Bristol Myers Squibb,;Lawrenceville, New Jersey, United States of America.;Worldwide Patient Safety, Epidemiology, Bristol Myers Squibb, Princeton, New;Jersey, United States of America.;Department of Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers;University, New Brunswick, New Jersey, United States of America. |
|---|
